New incentives in drug development would help bring more affordable medicines to market, including those to combat antimicrobial resistance, FDA acting commissioner Janet Woodcock said Wednesday
“I believe there probably are some adjustments to be made the ecosystem,” Woodcock said at The Hill’s Future of Healthcare event. “We have too little innovation to make affordable drugs.”
Woodcock was part of the Trump administration’s successful effort to get a Covid-19 vaccine to the country in record time and may leverage that experience to fight other public health threats like dangerous drug-resistant bacteria.
Woodcock also served as the longtime head of ...